This brand name is authorized in United States.
The drug EXDENSUR contains one active pharmaceutical ingredient (API):
1
|
UNII
D16EQP0KKH - DEPEMOKIMAB
|
|
Depemokimab is an IL-5 antagonist (humanized IgG1 kappa monoclonal antibody), which binds to IL-5 with a dissociation constant of 10.5 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the cell surface. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Inflammation is an important component in the pathogenesis of asthma. Depemokimab, by inhibiting IL-5 signaling, reduced the production and survival of eosinophils; however, the mechanism of depemokimab-ulaa action in asthma has not been definitively established. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| EXDENSUR Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| US | FDA, National Drug Code | 0173-0927 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.